Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01555268
Recruitment Status : Completed
First Posted : March 15, 2012
Last Update Posted : February 15, 2017
Sponsor:
Collaborators:
National Cancer Institute (NCI)
Amgen
Information provided by (Responsible Party):
Roswell Park Cancer Institute

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : September 24, 2013
Actual Study Completion Date : August 3, 2016